Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva tecnología de administración de fármacos para el tratamiento de la degeneración macular relacionada con la edad

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOGR20151123002
Publicado:
08/12/2015
Caducidad:
08/12/2016
Resumen:
Una pyme griega ha desarrollado un sistema de administración de fármacos para el tratamiento de la degeneración macular relacionada con la edad. Una combinación de medicamentos de factor de crecimiento anti vascular epitelial (anti-VEGF) y medicamentos antineurodegenerativos se administra en la parte posterior del ojo mediante un implante hecho de un hidrogel térmicamente sensible, colocado en la esclerótica cerca del nervio óptico. Se buscan socios con el fin de establecer acuerdos de licencia, cooperación técnica, investigación y comercialización con asistencia técnica.


Details

Tittle:
A novel drug delivery technology for treatment of age-related macular degeneration
Summary:
A Greek SME has developed a drug delivery system for the treatment of age-related macular degeneration. A combination of anti-vascular-epithelial-growth-factor (anti-VEGF) -Y- anti-neurodegeneration drugs is delivered to the posterior eye through an implant made out of a thermally-sensitive hydrogel, placed on the sclera close to the optical nerve. They are looking for commercial agreement with technical assistance, financial, licensing -Y- technical cooperation and are open to research cooperation.
Description:
Age-related macular degeneration (AMD) is currently treated with intravitreal injection of anti-vascular-epithelial-growth-factor (anti-VEGF) drugs. A different drug delivery system has been studied in silico and its results compare favorably to data in vitro and from clinical trials.
The proposed drug is a combination of anti-VEGF, which prevents violation of the blood-retina barrier (BRB), and anti-neurodegeneration drugs, which enhance the protection of ARPE-19 cells against oxidative stress and clear the debris from the affected retina.
A thermally-sensitive hydrogel, which has a critical temperature of 33 degrees celsius containing the drug is placed in the posterior eye, on the sclera close to the optical nerve. The hydrogel below 33 degrees celsius swells, adsorbing water and is loaded with the drug. When placed on the sclera at body temperature, which is above 33 degrees celsius,the hydrogel deswells thus facilitating the release of the high molecular weight drug molecules. The drug molecules cross the various layers from the sclera to the choroid and the retina by molecular diffusion. Through in silico studies with a physiologically correct model of the human study it is shown that sustained delivery of the drug can maintain therapeutic levels for up to 8 weeks, comparable to the time observed for intravitreal injections which are more risky and cause high discomfort to doctors and patients alike.

The Greek SME is seeking strategic partners from SME -Y- industry in the pharma and/or medical device sectors for further R-Y-D development and commercialisation of the novel technology through technical and research cooperation as well financial, licensing and commercial agreement with technical assistance.
Advantages and Innovations:
- More effective therapeutically than the single use of one drug, anti-VEGF or anti-neurodegeneration drugs
- Non invasive: Superior in comfort to currently practiced delivery of anti-VEGF agents by intravitreal injection and equally as effective in sustained delivery as the latter.
Stage of Development:
Concept stage
IPs:
Secret Know-how,Granted patent or patent application essential

Partner sought

Type and Role of Partner Sought:
Type -Y- specific area of activity of partner sought:
SMEs -Y- industry in the pharma sector and/or developers and/or manufactures of medical devices.

Task to be performed:
Co-developing the device; investing in the R-Y-D; marketing the novel implant under the cooperation types enumerated.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Greek

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06001013 Tecnología médica / ingeniería biomédica